HeartSciences Inc. (HSCS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -8 | -9 | ||||||
| Net profit | $m | -4 | -2 | -5 | -6 | -7 | -9 | -9 | -10 |
| EPS reported | $ | -3.48 | -3.20 | ||||||
| Operating cashflow per share | $ | -2.83 | -2.35 | ||||||
| Capex per share | $ | 0.02 | 0.01 | ||||||
| FCF per share | $ | -2.85 | -2.36 | ||||||
| Free cash flow | $m | -7 | -1,324 | ||||||
| Net debt | $m | 1,965 | -307 | ||||||
| Book value equity | $m | 226 | - | ||||||
| Book value per share | $ | 85.90 | 0.07 | ||||||
| Number of shares | m | 2.63 | 3.67 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.02 | 28.82 | ||||||
| P/S LTM | x | 1,185.36 | 728.76 | ||||||
| P/FCF LTM | x | -0.69 | -0.00 | ||||||
| EV/EBITDA LTM | x | -659.51 | -0.55 | ||||||
| EV/Sales LTM | x | 529,046.67 | -381,669.09 | ||||||
| Earnings Yield LTM | % | -0.18% | -1.40% | ||||||
| FCF Yield | % | -145.93% | -40214.5% | ||||||
| Quality | |||||||||
| ROE | % | -4.05% | -358.44% | ||||||
| ROIC | % | -0.20% | -2.02% | ||||||
| Operating margin | % | -1947.9% | -1947.9% | ||||||
| Gross margin | % | -29.82% | -29.82% | ||||||
| FCF/Sales | % | -172983.5% | -172983.5% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -0.71% | -75.70% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.00 | -330.72 | ||||||
| Net Debt/EBITDA | x | -270.99 | 196.47 | ||||||
| EBIT/Net interest | x | -11.17 | -11.17 | ||||||
| Net debt/market cap | % | +707.50% | +81.42% | ||||||
| Net debt/Equity | x | 8.71 | - | ||||||
| Gross debt/equity | x | 17.46 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free